Thanks Chapel, was really good to see that, first issue since EASL:.
Note, this is a very positive statement, not just relevant to New Zealand-
“Dr James Freeman received a long- standing ovation following his presentation at EASL in Barcelona…..”
And this from NZHF Clinical Director ; ” the international liver specialist community recognise how he is helping to make generic DAA’s available at a fraction of the cost…..”
Genotype 3 30 years, 2x treatment interferon/ribavirin non responder. Cirrhosis 17 years. Fibroscan, decompensating, 40 down to 22 by 29/3/16- now down to 6.5, normal, no cirrhosis. Started Buyers Club Sof/Dac 14 Nov 15. SVR 12 29/0716